- In March 2024, Juvisé Pharmaceuticals, a prominent French pharmaceutical company, has secured the global commercial rights (excluding the United States and Canada) for Ponvory (ponesimod), a treatment for adults with active forms of relapsing multiple sclerosis (RMS), through an acquisition from Actelion Pharmaceuticals Ltd., a subsidiary of Johnson & Johnson. This strategic acquisition underscores Juvisé Pharmaceuticals' expansion into the global multiple sclerosis treatment market, allowing the company to leverage Ponvory’s potential to address the growing demand for effective disease-modifying therapies
- In February 2024, Roche Pharma India introduced Ocrevus (ocrelizumab), a monoclonal antibody drug, as a disease-modifying therapy (DMT) for both relapsing multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in India. This launch marks a significant milestone in Roche Pharma India’s commitment to advancing treatment options for multiple sclerosis (MS) patients
- In October 2023, Biogen released positive Phase 3 clinical trial results for their investigational drug, BIIB098, highlighting significant efficacy in reducing disease activity and slowing disability progression in individuals with relapsing forms of multiple sclerosis (MS). These findings represent a substantial advancement in MS treatment, offering new hope for patients and clinicians alike. The implications of this breakthrough are also highly relevant to the global Multiple Sclerosis Market. As the need for more effective treatment options grows, BIIB098’s potential to address critical gaps in managing relapsing MS may contribute to the expansion of the market
- In November 2022, Roche introduced a subcutaneous formulation of Ocrevus (ocrelizumab) in the United States for the treatment of relapsing forms of multiple sclerosis (MS) and primary progressive MS, offering patients an additional method of administration for this widely used therapy. This development holds significant relevance to the global Multiple Sclerosis Market. By providing patients with more flexible administration options, Roche’s new formulation of Ocrevus is expected to enhance patient adherence and satisfaction, potentially driving greater market penetration
- In August 2020, Novartis announced the launch of Kesimpta (ofatumumab) following its approval by the U.S. Food and Drug Administration (FDA). Kesimpta is the first and only self-administered, targeted B-cell therapy for individuals with relapsing multiple sclerosis (RMS). Combining robust efficacy with a favorable safety profile, Kesimpta offers the added benefit of at-home self-administration, addressing a critical need in the treatment of RMS. This development holds considerable significance for the global Multiple Sclerosis Market. By providing an innovative treatment option that enhances patient convenience and adherence, Kesimpta is poised to drive further growth in the MS therapeutic landscape
